Menu
ncarol.com
  • Home
  • Music
  • Books
  • Manufacturing
  • Book Release
  • Asheville Music
  • Health
  • Business
  • Real Estate
ncarol.com

North Carolina: Biopharmaceutical Manufacturer Merck Expands Again in Wilson County with $57 Million Investment
ncarol.com/10036934

Trending...
  • FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Heritage at Manalapan Welcomes New Sales Team as Luxury Single-Family Home Community Continues to Grow
  • Parents No Longer Have to Wait 3 Weeks for a Sleep Consultant: Nora Talks Tonight, Stays for 5 Days, Costs $89
Merck (NYSE: MRK), a leading global biopharmaceutical company, will invest $57 million and create 55 jobs in Wilson, Governor Roy Cooper announced today. The expansion will establish a filling and packaging line for the company's RotaTeq® vaccine.

"Merck is a cornerstone of pharmaceutical development and manufacturing, and good jobs will continue to grow with today's announcement in Wilson," said Governor Cooper.

Merck, with headquarters in Kenilworth, New Jersey and known as MSD outside of the United States and Canada, discovers and develops medicines and vaccines for many of the world's most challenging diseases.  The company operates in more than 140 countries and stays at the forefront of research to advance the prevention and treatment of diseases that threaten people and communities around the world.

The company's RotaTeq® vaccine is used to prevent rotavirus gastroenteritis in children. Rotavirus gastroenteritis can cause fever, vomiting and diarrhea that can be severe and lead to dehydration and hospitalization. Merck's investment at the Wilson site will increase the company's overall supply of this important medicine.

"Merck is delighted to announce its second significant investment at our Wilson plant in less than a year," said Sanat Chattopadhyay, Executive Vice President and President, Merck Manufacturing Division. This latest commitment will enable us to introduce a new and innovative filling and packaging technology to assist in the production of our important RotaTeq® vaccine. We appreciate all the support we've received for this project from Governor Cooper, Secretary Copeland and his staff, and from Wilson County."

More on ncarol.com
  • Who Is KayeDinero? The Asheville Artist Also Builds Software and Trading Systems
  • Leaping Cat Creative Takes Shape Around the Problems Nobody Quite Owns
  • White Coat Financial Partners Announces Launch of Next Generation Practice Optimization Software
  • Kerri Lawless Introduces New Home-Selling Option for Local Homeowners
  • As Boone Takes Art to the Streets, KayeDinero Asks What Makes Creativity Human

Today's commitment is the second major expansion Merck has announced in North Carolina in 2019. In July, the company announced it would begin producing its GARDASIL® and GARDASIL 9® recombinant human papillomavirus (HPV) vaccine in the state, supported by expansion of company facilities in Durham and Wilson. In the earlier announcement, the company committed to invest more than $680 million in the state, with $30 million of that investment earmarked for Wilson.

"Nothing beats first-hand knowledge, and Merck's previous experience in our state gave them the confidence to bring this new business line here," said North Carolina Commerce Secretary Anthony M. Copeland.  "In just one year, this company has now invested $737 million in North Carolina, proving again that we're a hotbed for the life science industry."

The North Carolina Department of Commerce led the state's support for the company during its site evaluation and decision-making process.

Although wages will vary depending on position, Merck's average salary for all the new positions will reach $59,273. The current average wage in Wilson County is $44,012.

A performance-based grant of $200,000 from the One North Carolina Fund will help facilitate Merck's expansion in Wilson County. The One NC Fund provides financial assistance to local governments to help attract economic investment and to create jobs. Companies receive no money upfront and must meet job creation and capital investment targets to qualify for payment. All One NC grants require a matching grant from local governments and any award is contingent upon that condition being met.

More on ncarol.com
  • FDA-Cleared Zeta TMS Robotic System Moves Toward Deployment as FDA, DARPA and Commercial Catalysts Converge: NRx Pharmaceuticals (N A S D A Q: NRXP)
  • Baird Medical Turns Global Expansion Into Tangible Growth: N A S D A Q: BDMD Posts 25% Revenue Surge as U.S. and International Markets Accelerate
  • Black Mountain Meets "Human Error": KayeDinero on What Technology Can't Reproduce
  • As Brevard Heads Into Mountain Song Weekend, KayeDinero Brings a Different Kind of WNC Sound
  • Why Did KayeDinero Put Haywood Road Into a Song?

"Merck is a valued employer in our region," said N.C. Senator Milton 'Toby' Fitch, Jr. "We welcome these additional jobs and the opportunities they will bring to our people."

"New growth from one of our area's most important industries is an exciting development," said N.C. Representative Jean Farmer-Butterfield. "Our community is proud to partner with Merck and we look forward to supporting the company's next phase of growth."

Partnering with N.C. Commerce and the Economic Development Partnership of North Carolina on this project were the North Carolina General Assembly, Wilson County, and the Wilson County Economic Development Office.

Filed Under: Government, State

Show All News | Disclaimer | Report Violation

0 Comments
1000 characters max.

Latest on ncarol.com
  • Defense & Space Strategy Strengthens as New Leadership Builds on NASA Results and Expanding Multi-Orbit Opportunities for Ascent Solar Technologies
  • STS Capital Partners is pleased to announce the appointment of Barry Brown as Vice President, Business Development
  • Local Ecomaids Owner Launches Healthy Home Reset Initiative for Triangle Families
  • Qscription Technologies and NEOPATHOLOGY CORP. Sign MOU to Bring FDA-Cleared Lung Imaging AI into U.S. Clinical Practice
  • Asheville Artist KayeDinero Asks What Happens When Technology Gets Too Human on "Human Error"
  • Heritage at Manalapan Welcomes New Sales Team as Luxury Single-Family Home Community Continues to Grow
  • Mandeville Pests May Pose Serious Health Risks for Your Family
  • TOLI North America's Floorleum Plain AdVantage Transforms Flooring Into a Wayfinding Tool
  • Share your workplace safety solutions at 2027 Applied Ergonomics Conference
  • Parents No Longer Have to Wait 3 Weeks for a Sleep Consultant: Nora Talks Tonight, Stays for 5 Days, Costs $89
  • May The Worst Team Win! Loserball Kicks Off Another NFL Season of Hilarious Mayhem
  • Black Women Living With, and Impacted by, HIV Express Gratitude, Grief, Joy, and Resilience
  • MainConcept Easy Video API Extends Full Transcoding to Arm and NETINT VPUs
  • From Detroit Streets to Blue Ridge Mountains: KayeDinero Finds a New Sound in Western North Carolina
  • Why Did KayeDinero Name a Song After Hendersonville?
  • Cruxy shortlisted for two Private Equity Wire® US Awards 2026: Advisory Firm of the Year (Overall) & Value Creation Consulting Firm of the Year
  • Did Asheville's BoomTown Weekend Inspire KayeDinero's Next Move?
  • From City Girl to Mountain Life: KayeDinero Releases "City Girl Saved" From Asheville
  • Lake Norman Philharmonic - Free Community Concert
  • Amaris Mint® Confirms UK Availability of Swedish-Made BioBoost Daily Nutrition Range
_catLbl0 _catLbl1

Popular on ncarol.com

  • Mito Health Passes One Million Lab Tests, Expands to Seven Categories of Preventive Health Testing - 156
  • Parksy (parksy.com) Tackles the Most Common Parking Problem Nobody Talks About: Finding the Car Again - 154
  • Phinge Exposes Massive AI Security Risks, Claiming Its Patented Hardware-Verified Architecture Is The Only Safeguard Against Surveillance Capitalism - 142
  • Free JavaScript Charting Library ProEssentialsJS Permits Commercial Use. Highcharts, SciChart and LightningChart Free Tiers Do Not - 138
  • 5X Gross Margin Improvement to Beat EPS Consensus; $54.6 Million 10-Year Contract Award Puts Cybersecurity Leader on Path to a $30 Million Run Rate - 132
  • BumbleBeeSmart Launches Dedicated Sensory Wall Panels Collection for Adults, Memory Care and Senior Living - 121
  • Robert DeMaio, Phinge CEO to Speak at 30th IIPLA 2026 on Securing IP, User Data & Digital Sovereignty via Verified App-less Tech. Attend the Live Q&A! - 121
  • Bspin Launches Lightning-Fast Crypto Gaming Expansion With Sportsbook, Poker, VIP Rewards, and Bitcoin Lightning Network Integration - 120
  • Project CIVICA Report Finds 10,680 Non-Citizen Indicators on New York Voter Rolls — Including 88 Records with Recent Voting History - 119
  • From Temecula Wine Country to Canyon Lake: Parkway Construction Transforms Outdoor Spaces for Inland Homeowners - 119

Similar on ncarol.com

  • As Canada and America Turn on Each Other, These Two Authors Stay On Speaking Terms
  • ANSI BSR Upholds Appeal of AFDE Member Andrew Sulner, MSFS, JD, finding the AAFS Academy Standards Board (ASB) Violated ANSI Essential Requirements
  • Pete Verbica: America Needs Statesmanship and Common Sense — Not a Cult of Personality
  • Project CIVICA Report Finds 10,680 Non-Citizen Indicators on New York Voter Rolls — Including 88 Records with Recent Voting History
  • Phinge & CEO Robert DeMaio Publicly Declare Cash Settlements or Judgments Alone Cannot & Will Not Remedy the Deep Public Harm of Infringing Its IP
  • Canadian Aerospace Defence Talent Expo (CADTE) Launches National TalentThread Initiative to Strengthen Canada's Future Workforce
  • Bronze Stevie Award Recognizes Satyadhar Joshi for AI Research and Public Policy Engagement
  • Former Prosecutor Opens Stegall Law in Summerville
  • Phinge CEO DeMaio Unveils Speech to Congress: User Data Sovereignty vs Tech Surveillance Capitalism, Asserting Foundational 2021 App-Less Patents & IP
  • Contracting Resources Group Named to Inc. 5000 for the Ninth Time
Copyright © 2026 ncarol.com | Contact Us | Privacy Policy | Terms of Service | Contribute